RxDoctor Payments Data

Brian Curtis, MD

Internal Medicine · Corvallis, ORNPI 1245289115

Payments from drug & device makers

What this record shows

This record is dominated by education: $35 of the $35 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Pfizer.

$35in general payments, 2019–2025

Across 1 payment — averaging $34.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$35
$2,409,867in research payments, 2019–2025

Across 433 payments — averaging $5565.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$1M
  • Eli Lilly$762K
  • Modernatx, Inc.$442K
  • Novo Nordisk AS$72K
  • Roche Diagnostics Operations, Inc.$60K
  • AstraZeneca$22K
  • plus $8K from 1 others

What the payments were for

  • Education$35100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer1$35

How this compares

$35 in reported general payments places this provider in the 55th percentile of 1,363 internal medicine providers in Oregon.

See all internal medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$96,578
Medicare patients
350
Services billed
2,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban273$278,960
JardianceEmpagliflozin67$70,711
OzempicSemaglutide46$69,945
TrulicityDulaglutide24$40,371
XareltoRivaroxaban22$33,071
MounjaroTirzepatide33$32,917
JanuviaSitagliptin Phosphate11$14,226
Breo ElliptaFluticasone/Vilanterol15$11,913
Levothyroxine Sodium572$10,219
VascepaIcosapent Ethyl18$8,141
Testosterone31$8,137
Atorvastatin Calcium592$7,890
Losartan Potassium529$6,755
Metoprolol Succinate314$5,458
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$5,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$278,960273 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,363 internal medicine providers in Oregon.

Other internal medicine in Corvallis

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →